Johnson & Johnson Has Signed An Agreement That Implies The Development Of A Vaccine For Alzheimer's Disease
Johnson & Johnson will direct 509 million dollars to develop a therapeutic vaccine against Alzheimer's disease, on which is a Swiss biotech company AC Immune works.
Step pilot bioproduct ACI- 35 is directed against tau protein which plays an important role in the development of Alzheimer's disease, along with beta-amyloid protein. Tau proteins are expressed predominantly in the central nervous system, while an excessively phosphorylated tau proteins constitute neurofibrillary tangles - clusters found in the brain in Alzheimer's disease. According to one of the versions, these clusters are one of the main causes of progressive neurodegeneration.
As the developers, ACI- 35 vaccine stimulates the immune system of the patient and contributes to the formation of antibodies that are specific to phosphorylated tau protein.
Currently, therapeutic vaccine undergpes the first stage of clinical trials during which the safety and tolerability are assessed.
It is worth noting that earlier AC Immune has entered into an agreement with Roche on the study of crenezumab, specific for the beta- amyloid protein.
- Oncologists Are Step Away From Vaccine Against Brain Tumors
- Sleeping Disorders Increase The Risk Of Alzheimer's Disease Development
- GlaxoSmithKline Has Successfully Tested A Vaccine Against Shingles